AI and computational design at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
11 organizations at TPD Summit 2026 present work in AI & computational design: 9 drug developers, 1 academic, government or non-profit body and 1 technology or service provider. Between them they bring 24 presentations to the program. Most represented: Nurix Therapeutics (4 on the program), Genentech (2 on the program), Protai (2 on the program). As of Oct 20, 2026.
Format
Top represented
Showing 1–11 of 11 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Nurix Therapeutics San Francisco, CA | ◇Industry Partner |
Clinical-stage biotech developing targeted protein degraders, including BTK degraders, for cancer and inflammatory diseases. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Tue Oct 27 12:30pm Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 9:00am Session Details to be Announced AI & computational design |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets medicines. | Talk Tue Oct 27 12:30pm Talk Thu Oct 29 9:30am Optimizing the Next Generation Degraders with Better Informatics, Descriptors & Predictive Modeling AI & computational design Panel Thu Oct 29 10:00am |
Combines proteomics and AI to discover drug targets, biomarkers and degraders. | Panel Tue Oct 27 3:10pm Talk Wed Oct 28 11:30am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design AI & computational designScreening, assays & proteomics Panel Thu Oct 29 10:00am |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases. | Talk Wed Oct 28 2:30pm Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling AI & computational design Talk Thu Oct 29 9:30am Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs) Degrader conjugates & tissue targeting |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company developing and marketing medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Tue Oct 27 5:00pm Modelling Targeted Protein Degradation from Cells to the Clinic AI & computational design Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Monte Rosa Therapeutics Boston, MA | |
Clinical-stage biotech developing molecular glue degraders from a proteomics-driven discovery platform, for cancer and immune diseases. | Chair Thu Oct 29 8:50am Chair’s Opening Remarks AI & computational design Talk Thu Oct 29 1:45pm Scaling Proteomics for High-Throughput CRBN Target Discovery Screening, assays & proteomics Chair Thu Oct 29 2:45pm Chair’s Closing Remarks Screening, assays & proteomics |
Eli Lilly Indianapolis, IN | |
Global pharmaceutical company; its TuneLab platform offers biotechs AI models trained on Lilly research data. | Talk Tue Oct 27 4:30pm Accelerating Drug Discovery with Lilly TuneLab’s Federated Computing Platform AI & computational design Panel Thu Oct 29 10:00am |
Georgia Institute of Technology Atlanta, GA | |
Public research university in Atlanta, Georgia. | Talk Mon Oct 26 3:15pm GlueFinder: A Data-Driven Framework for the Rational Discovery of Molecular Glues AI & computational designDegrader discovery & design Panel Tue Oct 27 3:10pm |
◇Innovation Partner | |
Hit-finding services company offering custom compound libraries, including molecular glue sets, chemistry services and computational design. | Talk Wed Oct 28 3:30pm From Design to Application: A CRBN Molecular Glue Library Derived from In-House & Literature-Validated CRBN Binders Screening, assays & proteomics |
GluBio Therapeutics Hangzhou, China | |
Molecular glue degrader developer with research centers in Shanghai and San Diego, working in cancer, autoimmune and genetic diseases. | Talk Wed Oct 28 2:30pm |
Biotech developing molecular glues and targeted immunotherapies with a computational discovery platform. | Panel Thu Oct 29 10:00am |
Instantly find 20 buyers in AI & computational design
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction